The News
Esmertec Extends Convertible Bond Repayment
29/03/2007
Shareholders invited to grant endorsement at AGM
DUEBENDORF-ZURICH, Switzerland – March 29, 2007 – Esmertec™ (SWX: ESMN), a focused provider of software and services to communications device manufacturers and mobile telecom operators, today invited its shareholders to its AGM held on April 19, 2007 at the Novotel, Zurich-Airport.
At this occasion, Esmertec is pleased to inform its shareholders that it expects to conclude favorable amendments of terms and conditions with investors in its convertible bonds due in September 2008 and September 2009 allowing for delayed repayments of the bonds and hence increasing the company's financial flexibility. Confirmation of investors representing 91% of convertible bond principal is expected in the next days.
According to new terms and conditions, conversion price, maturity date and non-conversion premium will be amended as follows:
For one third of the bond principal, the conversion price is reduced from CHF 16.20 to CHF 13.00 in exchange for the maturity being extended by one year and non-conversion premium is increased from 18.5% to 23.5% such that overall yield on the instrument remains unchanged.
For one third of the bond principal, the conversion price is reduced from CHF 16.20 to CHF 11.00 in exchange for the maturity being extended by two years and non-conversion premium is increased from 18.5% to 28.5% such that overall yield on the instrument remains unchanged.
For the last third of the bond principal, conversion price, maturity and non-conversion premium remain unchanged.
In order to meet the reduced conversion prices, a maximum capital increase of 496,040 new shares or less than 3% of total issued ordinary capital is needed. In agenda item 5.1, shareholders will be asked to vote on creating new conditional capital of 496,040 shares. However, to maintain the same overall potential dilution to issued ordinary capital, the Board of Directors is proposing in agenda item 5.2 to reduce authorized capital by 496,040 shares. The remaining 154,983 shares of authorized capital are expected to be used primarily in connection with the final earn-out payment to the sellers of Cellicium.
Furthermore, shareholders are invited to re-elect board members. The Board of Directors proposes that Hans-Ulrich Müller, Jean Schmitt and Ulrich Schumacher be re-elected for an additional one-year term of office. Roland Manger, Bernd Pfister and Tony Reis whose terms of office expire at this General Meeting do not stand for reelection, and Chase Bailey has resigned effective this General Meeting. Thereafter, Esmertec's Board of Directors is expected to consist of seven members.
As of today, the Annual Report of Esmertec AG is available for inspection at the Company's registered office (Esmertec AG, Lagerstrasse 14, 8600 Dübendorf) or can be downloaded from the Company's website (www.esmertec.com/investor_relations/reports.shtml).
This communication contains forward-looking statements based on current expectations and assumptions of the company's management, and involve certain risks and uncertainties. The forward-looking statements contained herein could be substantially impacted by risks and influences that are not foreseeable at present, so that actual results may vary materially from those anticipated, expected or projected.
About Esmertec
Esmertec is a focused provider of software and services to communications device manufacturers and mobile telecom operators. The company provides software platforms that enable the deployment of content and applications in devices and over servers. Customers include mobile telecom operators and manufacturers of mobile handsets, set-top boxes and interactive televisions. Esmertec's software and service capabilities excel with its reliability as well as fast and local execution. Founded in 1999, Esmertec is headquartered in Zurich, Switzerland with subsidiaries in China, France, South Korea, and the USA, and offices in Taiwan and the UK. Since 2005, Esmertec has been listed on the SWX Swiss Exchange (ESMN).
Investor Relations contact
Deborah Choate , CFO
Phone +41 44 823 8954
dchoate@esmertec.com
Media contact
Jan Gregor IR Firm
Phone + 41 43 244 8154
esmertec@irfirm.biz
Esmertec and Jbed are trademarks of Esmertec AG. Java is a trademark of Sun Microsystems Inc. Other company, product and service names may be trademarks of their respective owners.
2007
- 04/01/2007
-
08/01/2007
Movetis NV conclut un premier tour de financement de 49 millions d'euros
- 08/01/2007
- 09/01/2007
-
08/01/2007
UPEK is named CES Best of Innovations 2007 Design and Engineering Award Winner
-
16/01/2007
FOVEA Pharmaceuticals SA obtains Exclusive Worldwide Rights on RdCVF Protein Therapy
-
18/01/2007
CoreValve announces the appointment of Dolf Meewis as Vice President of International Sales
-
22/01/2007
INSIDE Launches High Performance MicroPass(R) L4-2G Contactless Platform
- 19/01/2007
-
15/01/2007
Varioptic and Creative Sensor Announce Liquid Lens Mass Production in China
-
24/01/2007
Addex starts Phase IIa Proof of Concept Study on ADX10061 for Smoking Cessation
- 31/01/2007
- 31/01/2007
- 31/01/2007
-
02/02/2007
Lenovo Mobile Selects Esmertec’s Jbed Software Solution to Power Major Platforms for Mobile Handsets
-
28/01/2007
UPEK Delivers First Biometric Security Software Solution for Windows Vista Operating System
- 02/02/2007
-
06/02/2007
Innate Pharma announces operating revenue of 8.4 million euros in 2006 and updates on its finances
-
06/02/2007
CPI Card Group Adopts INSIDE's Next-Generation MicroPass L4-2G Contactless Platform
- 08/02/2007
-
13/02/2007
Discover® Network certifies Inside Contactless chip for contactless payment cards & devices
- 14/02/2007
-
28/02/2007
IDM Pharma Announces the Completion of Enrollment in Two Phase II Trials of Uvidem(R) in Melanoma
- 02/03/2007
-
08/03/2007
7TM Pharma advances the next first-in-class obesity compound into clinical development
- 08/03/2007
-
19/02/2007
Inside Contactless nominated for Performance AWARD Les Echos
-
08/03/2007
Streamezzo expands executive team with general manager for EMEA
- 13/03/2007
- 20/03/2007
- 26/03/2007
- 28/03/2007
-
29/03/2007
Esmertec Extends Convertible Bond Repayment
- 26/03/2007
-
03/04/2007
EmailVision : Forte progression du Résultat d'Exploitation au 2nd semestre 2006
- 03/04/2007
-
30/03/2007
Inside Extends Smart Card Alliance Involvement Within the Leadership Council
- 05/04/2007
- 10/04/2007
- 10/04/2007
- 17/04/2007
- 17/04/2007
- 08/03/2007
- 20/04/2007
-
20/04/2007
Addex reports positive results in Phase IIa clinical trial with ADX10059 in Migraine
-
26/04/2007
E-Mail Vision Forte croissance de l’activité au 1er trimestre 2007
-
26/04/2007
Innate Pharma S.A. announced two additional clinical trials for its IPH 1101 drug candidate
- 02/05/2007
- 03/05/2007
-
16/05/2007
ReVolt Technology and Phonak AG to Develop Rechargeable Zinc-air Battery Technology for Hearing Aids
- 16/05/2007
- 17/05/2007
-
30/05/2007
Esmertec Announces Robust Operational Performance in Q1 2007
- 05/06/2007
- 04/06/2007
- 01/06/2007
-
06/06/2007
Inside's Micropass reaches new milestone with 20 million units sold
- 07/06/2007
-
06/06/2007
MOVETIS Announces Start of A Phase IIa trial for M0002 in Ascites
- 07/06/2007
-
07/06/2007
NOXXON Pharma announces appointment of Dr. Walter Wenninger as Chairman of the Board
- 12/06/2007
-
23/05/2007
Streamezzo closes its second round of financing with investment from Qualcomm Ventures
- 10/06/2007
- 18/06/2007
-
18/06/2007
Ablynx identifies novel nanobodies® achieving second milestone in Procter & Gamble collaboration
-
21/06/2007
Innate Pharma has received approval for its phase II trial with IPH 1101 in HCV in France
- 21/06/2007
-
25/06/2007
Innate Pharma annonce un nouvel essai clinique avec IPH 2101 (NN 1975), le premier sous U.S ind
- 25/06/2007
- 27/06/2007
- 27/06/2007
-
29/06/2007
Frost & Sullivan Bestows its 2007 global contactless innovation & advancement award
-
02/07/2007
Ablynx announces interim results of first NANOBODY® Phase I study of ALX-0081 (anti-VWF)
- 06/07/2007
-
03/07/2007
Diatos Completes a Series D €9.4 Million Private Financing Round
-
10/07/2007
Sensitive Object and Tyco Electronics' Elo TouchSystems Business Sign License Agreement
- 09/05/2007
- 25/07/2007
-
25/07/2007
Addex Pharmaceuticals : Résultats Financiers du Premier Semestre 2007
-
30/05/2007
CTS International acquires Planet EV product line from Ericsson
- 05/07/2007
- 14/08/2007
- 06/08/2007
- 16/08/2007
- 24/07/2007
- 20/07/2007
-
24/07/2007
CoreValve named to Red Herring magazine’s ‘top 100’ North American private companies
-
22/08/2007
IBM Acquires WebDialogs to Expand Web Conferencing Capabilities in Industry-Leading Lotus Sametime
- 27/08/2007
- 27/08/2007
-
23/08/2007
Software and IT Executives Learn Growth and Exit Strategies at WFS' Fourth Annual London Conference
-
30/08/2007
Stentys appoints Hikmat Hojeibane as Chief Technology Officer
- 06/09/2007
- 07/09/2007
-
17/09/2007
DBV Technologies expands management team and moves to new facilities in Paris
-
18/09/2007
Inside chosen for world's first NFC-enabled M-payment rollout
-
19/09/2007
Sofinnova Partners Names Chika Yoshinaga Vice President, Asia
-
19/09/2007
Sofinnova Partners nomme le Dr Chika Yoshinaga Vice President, en charge de l’Asie
- 24/09/2007
- 24/09/2007
- 25/09/2007
-
25/09/2007
VoluBill raise 10.5 Million Euros to fund aggressive growth strategy
-
25/09/2007
VoluBill lève 10,5 Millions d’Euros pour financer une stratégie de croissance agressive
-
24/09/2007
First-in-man milestone reported for the Stentys bifurcated drug-eluting stent
-
25/09/2007
Purple Labs Raises .5 Million USD in Initial Round of Venture Capital Financing
-
29/09/2007
7TM Pharma hires experienced Director of Business Development and Medical Director
- 24/09/2007
-
01/10/2007
Noxxon Pharma appoints Dr. Joachim Kempeni as Chief Medical Officer
- 04/10/2007
- 10/10/2007
- 19/10/2007
-
22/10/2007
Diatos announces the successful completion of Phase I trial for DTS-201, a novel doxorubicin prodrug
- 23/10/2007
- 24/10/2007
- 23/10/2007
- 30/10/2007
-
30/10/2007
Kyocera WIRELESS and Inside Contactless join forces on NFC integration
- 30/10/2007
- 01/11/2007
-
05/11/2007
Inside Contactless empowers new generation NFC payment project with carrier Far EasTone in Taïwan
- 05/11/2007
- 06/11/2007
-
06/11/2007
ABLYNX RAISES €75 MILLION IN SUCCESSFUL IPO - Largest ever biotech IPO on Euronext Brussels
- 12/11/2007
- 23/10/2007
- 23/10/2007
- 07/11/2007
-
09/11/2007
INSIDE Contactless ranked in the Deloitte Technology Fast 50 list for South of France
-
09/11/2007
Noxxon Pharma announces research & development alliance with Roche regarding inflammatory diseases.
- 13/11/2007
- 13/11/2007
-
13/11/2007
DBV Technologies stengthens board of Directors and Scientific Advisory Board
- 13/11/2007
- 14/11/2007
- 15/11/2007
- 05/11/2007
- 12/11/2007
-
16/11/2007
Esmertec reduces debts and increases equity by early conversion of outstanding convertible bonds
-
03/12/2007
Addex and Merck & Co. Collaborate to Develop Drugs for Parkinson’s Disease
- 04/12/2007
-
04/12/2007
Preglem SA announces CHF 36 million Series B funding and new licencing agreement with HRA Pharma
-
27/11/2007
FOVEA Pharmaceuticals Enter Into a Research Collaboration in Ophthalmology With GENZYME Corporation
- 27/11/2007
-
11/12/2007
Nokia Growth Partners leads Series C investment round in INSIDE Contactless
- 12/12/2007
-
13/12/2007
Ascendis Pharma A/S Completes €17.6 Million Series-A Financing
-
16/12/2007
Movistar selects Esmertec’s USSD platform for Latin American operations
-
13/12/2007
Mobile Digital Media Named Exclusive Retail Publisher and Distributor for Atkins™ Carb Counter
-
17/12/2007
Ablynx reports positive phase I results for its anti-thrombotic nanobody®, ALX-0081
- 20/12/2007
-
05/12/2007
SFR adopte la plate-forme de Streamezzo pour optimiser son nouveau portail rich media
-
05/12/2007
SFR adopts Streamezzo's software platform to power new rich media portal
-
10/12/2007
Streamezzo names Alex Middleton General Manager for Americas
- 27/12/2007
- 10/04/2007